LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

Search

Kymera Therapeutics Inc

Open

BrancheGesundheitswesen

87.01 1.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

83.94

Max

87.81

Schlüsselkennzahlen

By Trading Economics

Einkommen

18M

-69M

Verkäufe

32M

34M

EPS

-0.71

Gewinnspanne

-201.467

Angestellte

253

EBITDA

18M

-67M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+37.02% upside

Dividenden

By Acuity

Nächstes Ergebnis

11. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-979M

6.1B

Vorheriger Eröffnungskurs

85.96

Vorheriger Schlusskurs

87.01

Nachrichtenstimmung

By Acuity

50%

50%

146 / 342 Ranking in Healthcare

Kymera Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Über Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat